Your browser doesn't support javascript.
loading
Myocarditis associated with COVID-19 vaccination.
Buoninfante, Alessandra; Andeweg, Arno; Genov, Georgy; Cavaleri, Marco.
Afiliação
  • Buoninfante A; Public Health Threats, European Medicines Agency, Amsterdam, The Netherlands. alessandra.buoninfante@ema.europa.eu.
  • Andeweg A; Public Health Threats, European Medicines Agency, Amsterdam, The Netherlands.
  • Genov G; Pharmacovigilance Office, European Medicines Agency, Amsterdam, The Netherlands.
  • Cavaleri M; Public Health Threats, European Medicines Agency, Amsterdam, The Netherlands. marco.cavaleri@ema.europa.eu.
NPJ Vaccines ; 9(1): 122, 2024 Jun 28.
Article em En | MEDLINE | ID: mdl-38942751
ABSTRACT
Following the start of the COVID-19 vaccination campaign, the adverse events of myocarditis and pericarditis were linked mainly to mRNA COVID-19 vaccines by the regulatory authorities worldwide. COVID-19 vaccines have been administered to several million people and the risk of myocarditis post COVID-19 vaccination has been characterised in great detail. At the present time the research data available are scarce and there is still no clear understanding of the biological mechanism/s responsible for this disease. This manuscript provides a concise overview of the epidemiology of myocarditis and the most prominent mechanistic insights in the pathophysiology of the disease. Most importantly it underscores the needed next steps in the research agenda required to characterize the pathophysiology of this disease post-COVID-19 vaccination. Finally, it shares our perspectives and considerations for public health.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: NPJ Vaccines Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: NPJ Vaccines Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Holanda